Clinical Trials Directory

Trials / Recruiting

RecruitingNCT02640911

An Observational Study on Atypical Antipsychotics Long-term Treatment Patients With Schizophrenia

Status
Recruiting
Phase
Study type
Observational
Enrollment
3,000 (estimated)
Sponsor
Shanghai Mental Health Center · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

This multi-centre study will evaluate the safety and related factors study of atypical antipsychotics long-term treatment in Chinese Patients with Schizophrenia. The atypical antipsychotics include quetiapine, olanzapine, risperidone, aripiprazole, ziprasidone, paliperidone , amisulpride , perospirone and clozapine. This is an open, cohort, multi-center observational clinical study. The main purpose is to evaluate the safety. And the second purpose is to evaluate the efficacy of atypical antipsychotics. The efficacy evaluations include symptoms, social function, recurrence rate and hospitalization. This study belongs to IV period post-marketing drugs research. Planned sample size is 3000 cases. Visits occurs at 0,4,8,13,26,52,78,104,130 and 156 weeks. The main indexes include physical examination, vital signs, abdominal circumference , laboratory tests (blood cell analysis/ blood biochemical tests / prolactin (PRL) / thyroxine, etc.), adverse events, 12-lead electrocardiogram( ECG), extrapyramidal syndrome(EPS )assessment, sexual function evaluation, medication and other subjective feelings. The second indexes include scales of Positive and Negative Syndrome Scale(PANSS),Clinical Global Impression-severity of Illness Scale(CGI-S), Calgary Depression Scale for Schizophrenia(CDSS),Personal and Social Performance Scale(PSP), the MOS 36一item Short Form Health Survey(SF-36), relapse rate, drug consolidation, medical-related expenses, income, drug plasma concentration and genetic information.

Conditions

Timeline

Start date
2010-11-01
Primary completion
2030-05-01
Completion
2033-05-01
First posted
2015-12-29
Last updated
2021-09-14

Locations

1 site across 1 country: China

Source: ClinicalTrials.gov record NCT02640911. Inclusion in this directory is not an endorsement.